Comparative Pharmacology
Head-to-head clinical analysis: AMBENYL versus TUXARIN ER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AMBENYL versus TUXARIN ER.
AMBENYL vs TUXARIN ER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
AMBENYL is a combination product containing codeine (opioid agonist) and bromodiphenhydramine (antihistamine). Codeine binds to mu-opioid receptors in the CNS, inhibiting ascending pain pathways and altering pain perception; bromodiphenhydramine antagonizes histamine H1 receptors, producing antitussive and sedative effects.
TUXARIN ER contains dextromethorphan, an NMDA receptor antagonist and sigma-1 receptor agonist, and bupropion, a norepinephrine and dopamine reuptake inhibitor. The combination is thought to modulate glutamatergic neurotransmission and enhance dopaminergic and noradrenergic signaling.
Each 5 mL contains codeine phosphate 10 mg and diphenhydramine hydrochloride 12.5 mg. Adults: 10 mL (2 teaspoonfuls) orally every 4-6 hours as needed; maximum 40 mL per day.
1 tablet orally every 12 hours; each tablet contains chlorpheniramine maleate 8 mg and phenylephrine HCl 20 mg.
None Documented
None Documented
Codeine: 2.5-3.5 h (terminal) with CYP2D6 poor metabolizers up to 6 h. Guaifenesin: 1-2 h.
The terminal elimination half-life (t1/2) of chlorpheniramine is approximately 14–25 h in adults, allowing twice-daily dosing. Pseudoephedrine has a shorter t1/2 of 5–8 h in normal renal function, but the ER formulation maintains therapeutic levels for 12 h. In renal impairment, pseudoephedrine half-life prolongs significantly, requiring dose adjustment.
Renal: 60% unchanged codeine, 20% codeine-6-glucuronide; biliary/fecal: 20% as metabolites. Guaifenesin: renal 95% as unchanged drug and metabolites.
TUXARIN ER is a combination antihistamine/decongestant. The antihistamine component (e.g., chlorpheniramine) is extensively metabolized via CYP450; its metabolites and parent drug (∼68% over 48 h) appear in urine as unchanged drug and metabolites. The decongestant (e.g., pseudoephedrine) is primarily excreted unchanged in urine (∼70–90%) with the remainder metabolized in liver; renal elimination is pH-dependent, with acidic urine increasing excretion. Fecal elimination is negligible (<5%).
Category C
Category C
Antitussive/Antihistamine Combination
Antitussive/decongestant combination